Itafos amends credit facilities, upsizes term loan commitment to USD 140 million
Bitget2026/09/29 21:10- Itafos amended its credit facilities with a lender syndicate led by RBC Capital Markets, with Texas Capital, PNC Capital Markets as joint lead arrangers.
- Refinancing replaces a USD 100 million term loan with USD 82.5 million outstanding, raising commitments to a USD 140 million term loan.
- Dedicated USD 30 million letter of credit facility retained; maturity for the amended term loan extended to Sept. 29, 2029.
- Revolving asset-based loan facility amended to extend maturity to Sept. 29, 2029; proceeds also repay outstanding ABL borrowings.
- At closing, amended term loan balance expected at USD 140 million; ABL undrawn; LC facility expected to have USD 12.5 million outstanding.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ido Ben-Natan: Frequent on-chain security incidents, AI agents will increase risks
BTC rebounds and breaks through 83,000 USDT, with a 24-hour decrease of 1%
Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly
The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Crypto prices
More
